OptimizeRx Corporation
OptimizeRx Corporation (OPRX) Revenue
Annual & quarterly revenue history · segment & region breakdown
OPRX · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsOptimizeRx Corporation trailing twelve-month (TTM) revenue is $0.11B, an increase of 18.78% year-over-year from $0.11B in FY2025.
Revenue trend
2025 – 2007 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.11B | +$0.02B | +18.78% |
| 2024-12-31 | $0.09B | +$0.02B | +28.81% |
| 2023-12-31 | $0.07B | +$0.01B | +14.53% |
| 2022-12-31 | $0.06B | +$0.00B | +1.89% |
| 2021-12-31 | $0.06B | +$0.02B | +41.51% |
| 2020-12-31 | $0.04B | +$0.02B | +76.08% |
| 2019-12-31 | $0.02B | +$0.00B | +15.99% |
| 2018-12-31 | $0.02B | +$0.01B | +74.86% |
| 2017-12-31 | $0.01B | +$0.00B | +56.45% |
| 2016-12-31 | $0.01B | +$0.00B | +7.35% |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income OptimizeRx Corporation receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
OptimizeRx Corporation reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from OptimizeRx Corporation's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
OPRX revenue · 4 questionsOPRX's trailing twelve-month (TTM) revenue is $0.11B. That is an increase of 18.78% year-over-year from $0.11B in FY2025.
▸ Source: FMP · OptimizeRx Corporation SEC filings · GAAP · OptimizeRx Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026